18 firms from the Science Park showcased their strength in the biotechnology exhibition to seize business opportunities.

18 firms from the Science Park showcased their strength in the biotechnology exhibition to seize business opportunities.

The Director of the Science Park, Hsu Mao-Hsin (center), poses for a photo with the annual outstanding biotechnology industry award winners.

The first major exhibition after the epidemic in Taiwan, the "2020 Asia Biotech Exhibition," opened with great enthusiasm at the Taipei Nangang Exhibition Center on July 23rd. The National Science and Technology Center for Innovative Applications led 18 exhibitors, including park manufacturers, biotech project subsidy manufacturers, and companies assisted by the Science Park Accelerator. Additionally, park manufacturers such as Cheng Hsun Biotech and Yi Tai Co., Ltd. were honored with the President's Award for Outstanding Biotech Industry. These achievements highlight the integration of cutting-edge biotechnology fields by the National Science and Technology Center, leveraging the solid technological foundation of the central precision machinery industry to establish an innovative medical ecosystem.

Minister of Science and Technology Wu Tsung-Tsong, accompanied by Director Hsu Mao-Hsin of the National Science and Technology Center, and others, visited the Ministry of Science and Technology Pavilion to cheer on the exhibitors. This year, the theme of the Ministry of Science and Technology Pavilion's exhibition area is "Biomedical Cluster in Science Parks, Leading Smart Healthcare." The park manufacturers showcase a collective exhibition demonstrating a wide range of fields including precision medicine, biopharmaceuticals, innovative healthcare, medical devices, and intelligent automation.

The Minister at the Science Park Exhibition Area for a group photo.
Director Hsu posing for a photo with the exhibiting companies.

The exhibition area at the Science Park is illuminated by nine prominent zones, featuring: SURGLASSES: Research and development of precise augmented reality surgical glasses Foresee-X. Cheng Yun Biomedical: 3D minimally invasive surgical imaging software and imaging technology to assist in medical operations and minimally invasive surgery. Yung Zip Pharmaceutical: Long-acting protein new drugs/Pegylation technology platform providing new hopes for cancer treatment. Ita Medical Materials: Innovative medical optoelectronic detection and laser therapy equipment. Jing De Biomedical: DEHseal wound cover powder, which has passed GMP and ISO certification, providing new options for medical treatment. Taiwan LiDe: The only company globally certified with international FSC certification for Ganoderma lucidum products. Zhenghan Biotech: Winner of the Annual Industrial Innovation Award this year, showingcasing smart agriculture through the research technology of phytochemicals. Elite Biotech: Nanotechnology applying the Nobel Prize-winning principle of electrospray ionization to develop electrospray ionization sprayers. New Liwang Precision Machinery: Enlisted in the National Mask Team, showing integrated services for the entire factory automation with three intelligence and two machines.

Director Hsu posing for a photo with the Lide team.

In addition, nine companies that received subsidies from the National Science and Technology Program or guidance from the National Science and Technology Accelerator are showcasing their expertise through individual or joint exhibitions. They leverage the advantages of the precision machinery industry in central Taiwan to drive capacity in areas such as smart assistive devices, minimally invasive surgery, and medical device research and development. Their collaborative efforts between industry, academia, and research institutions are presented in various exhibition zones.

The National Science and Technology Program emphasizes that the 2020 Asia Biotech Expo vividly showcases the capabilities and research achievements of the park's manufacturers in cutting-edge biotechnology fields. It also helps attract biotechnology companies to collectively build an innovative medical ecosystem. In the future, the National Science and Technology Program will continue to integrate the top-notch biotechnology and medical device research and manufacturing capabilities in central Taiwan. It will lead park manufacturers to advance in research and development and assist in expanding overseas markets, aligning with international standards and showcasing Taiwan's biotechnology capabilities to the world.


Related News
#techlife #China Times

en_US